Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
The gross margin is 0.00% as of the fiscal period ended Tuesday, June 30, 2026.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 0.00%.
GROSS MARGIN
0.00%
GROSS MARGIN AVG TTM
0.00%
GROSS MARGIN AVG 3Y
0.00%
GROSS MARGIN AVG 5Y
0.00%
GROSS MARGIN AVG 10Y
N/A
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
41.76%
median of 631 covered companies
CURRENT VS SECTOR MEDIAN
-100.00%
vs the sector median at left
Market Cap
$13.72M
Gross Margin
64.68%
TTM Avg
63.93%
3Y Avg
63.08%
5Y Avg
61.52%
Market Cap
$13.25M
Gross Margin
-486.44%
TTM Avg
-208.47%
3Y Avg
-109.22%
5Y Avg
-72.81%
Market Cap
$14.01M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$13.10M
Gross Margin
71.61%
TTM Avg
70.70%
3Y Avg
67.95%
5Y Avg
69.37%
Market Cap
$12.86M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$14.56M
Gross Margin
95.88%
TTM Avg
95.90%
3Y Avg
96.27%
5Y Avg
96.83%
Market Cap
$12.44M
Gross Margin
-137.55%
TTM Avg
-73123.88%
3Y Avg
-36779.95%
5Y Avg
-24519.97%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| IN8bio, Inc. (INAB) | $13.62M | 0.00% | 0.00% | 0.00% | 0.00% |
| Vyome Holdings, Inc. (HIND)vs › | $13.72M | 64.68% | 63.93% | 63.08% | 61.52% |
| Optimi Health Corp. (OPTH)vs › | $13.25M | -486.44% | -208.47% | -109.22% | -72.81% |
| Citius Pharmaceuticals, Inc. (CTXR)vs › | $14.01M | 0.00% | 0.00% | 0.00% | 0.00% |
| Cytosorbents Corporation (CTSO)vs › | $13.10M | 71.61% | 70.70% | 67.95% | 69.37% |
| Cellectar Biosciences, Inc. (CLRB)vs › | $12.86M | 0.00% | 0.00% | 0.00% | 0.00% |
| Obsidian Therapeutics Inc. (OBX)vs › | $14.39M | N/A | N/A | N/A | N/A |
| Karyopharm Therapeutics Inc. (KPTI)vs › | $14.56M | 95.88% | 95.90% | 96.27% | 96.83% |
| Dare Bioscience, Inc. (DARE)vs › | $12.44M | -137.55% | -73123.88% | -36779.95% | -24519.97% |
| IRIDEX Corporation (IRIX)vs › | $12.17M | 36.23% | 36.65% | 39.59% | 41.13% |
Gross Margin
0.0%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 0.00% |
| 2026-03-31 | 0.00% |
| 2025-12-31 | 0.00% |
| 2025-09-30 | 0.00% |
| 2025-06-30 | 0.00% |
| 2025-03-31 | 0.00% |
| 2024-12-31 | 0.00% |
| 2024-09-30 | 0.00% |
| 2024-06-30 | 0.00% |
| 2024-03-31 | 0.00% |
| 2023-12-31 | 0.00% |
| 2023-09-30 | 0.00% |
| 2023-06-30 | 0.00% |
| 2023-03-31 | 0.00% |
| 2022-12-31 | 0.00% |
| 2022-09-30 | 0.00% |
| 2022-06-30 | 0.00% |
| 2022-03-31 | 0.00% |
| 2021-12-31 | 0.00% |
| 2021-09-30 | 0.00% |
| 2021-06-30 | 0.00% |
| 2021-03-31 | 0.00% |
| 2020-12-31 | 0.00% |
| 2020-09-30 | 0.00% |
| 2020-06-30 | 0.00% |
| 2020-03-31 | 0.00% |
| 2019-12-31 | 0.00% |
| 2019-09-30 | 0.00% |
| 2019-06-30 | 0.00% |
| 2019-03-31 | 0.00% |
| 2018-06-30 | 0.00% |
| 2018-03-31 | 0.00% |
